Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics.
Adolescent
Adult
Aged
Aged, 80 and over
Animals
Bone Marrow
/ immunology
Cell Lineage
Cell Movement
Cells, Cultured
Child
Child, Preschool
Disease Models, Animal
Female
Granulocyte-Macrophage Progenitor Cells
/ immunology
Humans
Inflammation
/ immunology
Inflammation Mediators
/ metabolism
Lymphadenopathy
/ immunology
Lymphatic System
/ immunology
Male
Mice, Inbred C57BL
Mice, Knockout
Middle Aged
Myeloid Progenitor Cells
/ immunology
Phenotype
Signal Transduction
Time Factors
Young Adult
bone marrow
circulation
endotoxemia
human
immunology
inflammation
lymphatics
medicine
mouse
myeloid progenitors
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
08 04 2021
08 04 2021
Historique:
received:
02
01
2021
accepted:
07
04
2021
pubmed:
9
4
2021
medline:
27
10
2021
entrez:
8
4
2021
Statut:
epublish
Résumé
Innate immune cellular effectors are actively consumed during systemic inflammation, but the systemic traffic and the mechanisms that support their replenishment remain unknown. Here, we demonstrate that acute systemic inflammation induces the emergent activation of a previously unrecognized system of rapid migration of granulocyte-macrophage progenitors and committed macrophage-dendritic progenitors, but not other progenitors or stem cells, from bone marrow (BM) to regional lymphatic capillaries. The progenitor traffic to the systemic lymphatic circulation is mediated by Ccl19/Ccr7 and is NF-κB independent, Traf6/IκB-kinase/SNAP23 activation dependent, and is responsible for the secretion of pre-stored Ccl19 by a subpopulation of CD205 When the body becomes infected with disease-causing pathogens, such as bacteria, the immune system activates various mechanisms which help to fight off the infection. One of the immune system’s first lines of defense is to launch an inflammatory response that helps remove the pathogen and recruit other immune cells. However, this response can become overactivated, leading to severe inflammatory conditions that damage healthy cells and tissues. A second group of cells counteract this over inflammation and are different to the ones involved in the early inflammatory response. Both types of cells – inflammatory and anti-inflammatory – develop from committed progenitors, which, unlike stem cells, are already destined to become a certain type of cell. These committed progenitors reside in the bone marrow and then rapidly travel to secondary lymphoid organs, such as the lymph nodes, where they mature into functioning immune cells. During this journey, committed progenitors pass from the bone marrow to the lymphatic vessels that connect up the different secondary lymphoid organs, and then spread to all tissues in the body. Yet, it is not fully understood what exact route these cells take and what guides them towards these lymphatic tissues during inflammation. To investigate this, Serrano-Lopez, Hegde et al. used a combination of techniques to examine the migration of progenitor cells in mice that had been treated with lethal doses of a bacterial product that triggers inflammation. This revealed that as early as one to three hours after the onset of infection, progenitor cells were already starting to travel from the bone marrow towards lymphatic vessels. Serrano-Lopez, Hegde et al. found that a chemical released by an “alarm” immune cell already residing in secondary lymphoid organs attracted these progenitor cells towards the lymphatic tissue. Further experiments showed that the progenitor cells travelling to secondary lymphoid organs were already activated by bacterial products. They then follow the chemical released by alarm immune cells ready to respond to the immune challenge and suppress inflammation. These committed progenitors were also found in the inflamed lymph nodes of patients. These findings suggest this rapid circulation of progenitors is a mechanism of defense that contributes to the fight against severe inflammation. Altering how these cells migrate from the bone marrow to secondary lymphoid organs could provide a more effective treatment for inflammatory conditions and severe infections. However, these approaches would need to be tested further in the laboratory and in clinical trials.
Autres résumés
Type: plain-language-summary
(eng)
When the body becomes infected with disease-causing pathogens, such as bacteria, the immune system activates various mechanisms which help to fight off the infection. One of the immune system’s first lines of defense is to launch an inflammatory response that helps remove the pathogen and recruit other immune cells. However, this response can become overactivated, leading to severe inflammatory conditions that damage healthy cells and tissues. A second group of cells counteract this over inflammation and are different to the ones involved in the early inflammatory response. Both types of cells – inflammatory and anti-inflammatory – develop from committed progenitors, which, unlike stem cells, are already destined to become a certain type of cell. These committed progenitors reside in the bone marrow and then rapidly travel to secondary lymphoid organs, such as the lymph nodes, where they mature into functioning immune cells. During this journey, committed progenitors pass from the bone marrow to the lymphatic vessels that connect up the different secondary lymphoid organs, and then spread to all tissues in the body. Yet, it is not fully understood what exact route these cells take and what guides them towards these lymphatic tissues during inflammation. To investigate this, Serrano-Lopez, Hegde et al. used a combination of techniques to examine the migration of progenitor cells in mice that had been treated with lethal doses of a bacterial product that triggers inflammation. This revealed that as early as one to three hours after the onset of infection, progenitor cells were already starting to travel from the bone marrow towards lymphatic vessels. Serrano-Lopez, Hegde et al. found that a chemical released by an “alarm” immune cell already residing in secondary lymphoid organs attracted these progenitor cells towards the lymphatic tissue. Further experiments showed that the progenitor cells travelling to secondary lymphoid organs were already activated by bacterial products. They then follow the chemical released by alarm immune cells ready to respond to the immune challenge and suppress inflammation. These committed progenitors were also found in the inflamed lymph nodes of patients. These findings suggest this rapid circulation of progenitors is a mechanism of defense that contributes to the fight against severe inflammation. Altering how these cells migrate from the bone marrow to secondary lymphoid organs could provide a more effective treatment for inflammatory conditions and severe infections. However, these approaches would need to be tested further in the laboratory and in clinical trials.
Identifiants
pubmed: 33830019
doi: 10.7554/eLife.66190
pii: 66190
pmc: PMC8137144
doi:
pii:
Substances chimiques
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK124115
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007439
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL135787
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI091627
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK113639
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM110628
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK090971
Pays : United States
Déclaration de conflit d'intérêts
JS, SH, SK, JS, JF, AW, PR, YR, LC, HG, HG, SL, IM, JS, DS, JC No competing interests declared
Références
Cell. 1999 Oct 1;99(1):23-33
pubmed: 10520991
Stem Cells. 2006 Jan;24(1):3-12
pubmed: 16449630
Nat Rev Immunol. 2008 May;8(5):362-71
pubmed: 18379575
Elife. 2018 Apr 05;7:
pubmed: 29620526
Blood. 2013 May 30;121(22):4567-74
pubmed: 23613522
Nat Rev Immunol. 2003 Feb;3(2):169-76
pubmed: 12563300
Methods Mol Biol. 2010;595:187-93
pubmed: 19941113
J Immunol. 2011 May 1;186(9):5367-75
pubmed: 21441445
Nat Metab. 2019 Feb;1(2):236-250
pubmed: 31620676
Cancer Cell. 2013 Jul 8;24(1):90-104
pubmed: 23845443
Cell Rep. 2014 Dec 24;9(6):2084-97
pubmed: 25533346
Leukemia. 2005 Jan;19(1):161-5
pubmed: 15510205
Mech Ageing Dev. 2010 Nov-Dec;131(11-12):718-22
pubmed: 21035480
J Clin Invest. 2010 Mar;120(3):907-23
pubmed: 20197626
Ann Otol Rhinol Laryngol. 2009 May;118(5):391-6
pubmed: 19548390
Immunity. 2015 Jan 20;42(1):159-71
pubmed: 25579427
Nat Med. 2001 Sep;7(9):1028-34
pubmed: 11533706
Blood. 2002 Sep 1;100(5):1734-41
pubmed: 12176895
Cell. 2013 May 23;153(5):1025-35
pubmed: 23706740
Nat Immunol. 2017 Feb;18(2):236-245
pubmed: 28024152
Cell. 2010 Oct 29;143(3):416-29
pubmed: 21029863
Blood. 2004 Jan 1;103(1):340-6
pubmed: 12969972
Blood. 2009 Jul 9;114(2):290-8
pubmed: 19357397
Nat Med. 2005 Aug;11(8):886-91
pubmed: 16025125
Exp Hematol. 1977 May;5(3):186-90
pubmed: 872907
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9897-902
pubmed: 23716692
Nat Immunol. 2001 Aug;2(8):675-80
pubmed: 11477402
Nature. 2010 Aug 12;466(7308):829-34
pubmed: 20703299
Am J Hematol. 1984 Apr;16(3):277-86
pubmed: 6711557
Immunol Rev. 2000 Oct;177:134-40
pubmed: 11138771
Annu Rev Immunol. 2004;22:129-56
pubmed: 15032576
Blood. 2011 Nov 3;118(18):4829-40
pubmed: 21908421
Immunity. 2003 Jul;19(1):71-82
pubmed: 12871640
Nat Immunol. 2007 Nov;8(11):1255-65
pubmed: 17893676
Nature. 2003 Jan 30;421(6922):547-51
pubmed: 12540851
J Exp Med. 2015 Mar 9;212(3):401-13
pubmed: 25687281
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
J Exp Med. 2005 Jun 6;201(11):1771-80
pubmed: 15939792
Cell. 2007 Nov 30;131(5):994-1008
pubmed: 18045540
Development. 2020 Apr 20;147(21):
pubmed: 32188632
J Immunol. 1998 Sep 1;161(5):2580-5
pubmed: 9725259
Cell Rep. 2018 Jan 30;22(5):1250-1262
pubmed: 29386112
J Exp Med. 1996 Apr 1;183(4):1797-806
pubmed: 8666936
Nature. 2013 Mar 14;495(7440):227-30
pubmed: 23434756
Science. 2006 Jan 6;311(5757):83-7
pubmed: 16322423
J Exp Med. 2010 Jan 18;207(1):17-27
pubmed: 20026661
J Immunol. 2012 Jun 15;188(12):5824-8
pubmed: 22586037
Cell Tissue Kinet. 1979 May;12(3):257-67
pubmed: 476774
Nat Immunol. 2019 Jul;20(7):802-811
pubmed: 31213716
Immunity. 2006 Jun;24(6):801-12
pubmed: 16782035
Science. 2001 Nov 30;294(5548):1933-6
pubmed: 11729320
Cell. 2008 Aug 8;134(3):485-95
pubmed: 18692471
Cell Tissue Kinet. 1972 Nov;5(6):467-79
pubmed: 4569900
Blood. 2008 Feb 15;111(4):2444-51
pubmed: 18055867
Mod Pathol. 2013 Jan;26 Suppl 1:S88-96
pubmed: 23281438
J Exp Med. 1998 Feb 16;187(4):655-60
pubmed: 9463416
Immunity. 2003 Sep;19(3):353-63
pubmed: 14499111
N Engl J Med. 2003 Apr 17;348(16):1546-54
pubmed: 12700374
J Immunol. 1999 Mar 1;162(5):2472-5
pubmed: 10072485
Blood. 2012 May 31;119(22):5144-54
pubmed: 22498741
Blood. 1980 Jan;55(1):77-81
pubmed: 6985804
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
Cell. 2018 Jan 11;172(1-2):147-161.e12
pubmed: 29328910
Transgenic Res. 1999 Aug;8(4):265-77
pubmed: 10621974
Nature. 2008 Mar 27;452(7186):442-7
pubmed: 18256599
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12694-9
pubmed: 11070085
Immunity. 2004 Jan;20(1):87-93
pubmed: 14738767
FEBS Lett. 1997 May 5;407(3):313-9
pubmed: 9175875
Cell Stem Cell. 2014 Apr 3;14(4):445-459
pubmed: 24561084
Cell Death Differ. 2006 May;13(5):816-25
pubmed: 16410796
Proc Natl Acad Sci U S A. 1988 Sep;85(17):6232-6
pubmed: 3413093
Trends Immunol. 2001 Feb;22(2):78-83
pubmed: 11286707
Mol Cell Biol. 2000 Jun;20(11):4106-14
pubmed: 10805752
J Endocrinol. 2009 Jun;201(3):309-20
pubmed: 19443863
J Exp Med. 2001 Jan 15;193(2):207-18
pubmed: 11148224
Nat Immunol. 2008 Jun;9(6):676-83
pubmed: 18469816
Cell Rep. 2013 May 30;3(5):1539-52
pubmed: 23707063